150 related articles for article (PubMed ID: 37648295)
1. New Approaches Towards Targeted Therapy for Childhood Neuroblastoma.
Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON
Anticancer Res; 2023 Sep; 43(9):3829-3839. PubMed ID: 37648295
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
3. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.
Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M
Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055
[TBL] [Abstract][Full Text] [Related]
4. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
[TBL] [Abstract][Full Text] [Related]
5. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
[TBL] [Abstract][Full Text] [Related]
6. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.
Armstrong AE; Danner-Koptik K; Golden S; Schneiderman J; Kletzel M; Reichek J; Gosiengfiao Y
J Pediatr Hematol Oncol; 2018 Jan; 40(1):31-35. PubMed ID: 28538090
[TBL] [Abstract][Full Text] [Related]
7. [High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].
Valteau-Couanet D; Schleiermacher G; Sarnacki S; Pasqualini C
Bull Cancer; 2018 Oct; 105(10):918-924. PubMed ID: 30290975
[TBL] [Abstract][Full Text] [Related]
8. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
10. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
Bradfield SM; Douglas JG; Hawkins DS; Sanders JE; Park JR
Cancer; 2004 Mar; 100(6):1268-75. PubMed ID: 15022296
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
12. Development of treatment strategies for advanced neuroblastoma.
Hara J
Int J Clin Oncol; 2012 Jun; 17(3):196-203. PubMed ID: 22588779
[TBL] [Abstract][Full Text] [Related]
13. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
Jain R; Trehan A; Menon P; Kapoor R; Kakkar N; Radhika S; Saxena AK; Mittal BR; Varma N; Samujh R; Bansal D
Pediatr Hematol Oncol; 2021 May; 38(4):291-304. PubMed ID: 33622164
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
15. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
16. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
[TBL] [Abstract][Full Text] [Related]
17. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
18. Value of surgical resection in children with high-risk neuroblastoma.
Englum BR; Rialon KL; Speicher PJ; Gulack B; Driscoll TA; Kreissman SG; Rice HE
Pediatr Blood Cancer; 2015 Sep; 62(9):1529-35. PubMed ID: 25810376
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation.
Seo ES; Shin M; Lim H; Cho HW; Ju HY; Cho YS; Yoo KH; Koo HH; Lee JW; Sung KW
Pediatr Blood Cancer; 2022 Jul; 69(7):e29502. PubMed ID: 34889513
[TBL] [Abstract][Full Text] [Related]
20. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
